The HLA-Cw06 allele may predict the response to methotrexate (MTX) treatment in Chinese arthritis-free psoriasis patients

MTX in genetically distinctive Chinese psoriatic patients remains less explored. The present study aimed to determine the impact of HLA-Cw*06 on MTX response in a Chinese psoriasis patient population. A total of 204 patients with psoriasis were enrolled in this study. Clinical data and DNA samples f...

Full description

Saved in:
Bibliographic Details
Published in:Archives of dermatological research 2023-07, Vol.315 (5), p.1241-1247
Main Authors: Mao, Manyun, Kuang, Yehong, Chen, Menglin, Yan, Kexiang, Lv, Chenzhi, Liu, Panpan, Lu, Yan, Chen, Xiang, Zhu, Wu, Chen, Wangqing
Format: Article
Language:English
Subjects:
Alleles
Arthritis, Psoriatic - genetics
Dermatology
East Asian People
Gene frequency
Gene polymorphism
Genetic Predisposition to Disease
Genotyping
Histocompatibility antigen HLA
HLA-C Antigens - genetics
Humans
Medicine
Medicine & Public Health
Methotrexate
Methotrexate - therapeutic use
Original Paper
Patients
Prediction models
Psoriasis
Psoriasis - drug therapy
Psoriatic arthritis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MTX in genetically distinctive Chinese psoriatic patients remains less explored. The present study aimed to determine the impact of HLA-Cw*06 on MTX response in a Chinese psoriasis patient population. A total of 204 patients with psoriasis were enrolled in this study. Clinical data and DNA samples from all patients were collected. The allele of HLA-Cw*06 genotyping was detected using direct Sanger sequencing. This study enrolled 204 patients with psoriasis, including 47 (23.04%) psoriatic arthritis patients, 157 (76.96%) patients free of psoriatic arthritis. Overall, 110 (53.92%) of all patients carried the HLA-Cw*06 allele. This frequency in patients with arthritis-free psoriasis was higher than that in those with psoriatic arthritis (58.59 vs. 38.30%, P  = 0.014). After 8 weeks of MTX treatment, the arthritis-free psoriasis patients, who tested positive for the HLA-Cw*06 allele, showed significant improvement compared to those who tested negative (For PASI50, 78.57 vs. 55.22%, P  = 0.02, and for PASI75, 51.11 vs. 34.33%, P  = 0.036). The psoriatic arthritis-free patients who carried the HLA-Cw*06 allele in combination with the ABCB1 rs1045642 CC genotype showed the highest improvement. A regression model containing HLA-Cw*06, rs1045642T > C, and initial PASI scores was used to construct the efficacy prediction model of MTX, which yielded AUC values of 73.2 and 75.6% for PASI50 and PASI75 to MTX, respectively, in arthritis-free psoriasis patients. The HLA-Cw*06 allele is associated with optimal response to MTX treatment in arthritis-free Chinese psoriasis patients. When combined with clinical indicators, the polymorphism explained more than 75% of the individual efficacy differences.
ISSN:1432-069X
0340-3696
1432-069X
DOI:10.1007/s00403-022-02498-x